A retrospective study to determine association between efficacy of anti-PD-1/PD-L1 therapy, types of TME based on PD-L1 expression, and density of CD8-positive TILs in advanced NSCLC patients
Latest Information Update: 30 Aug 2021
At a glance
- Drugs Atezolizumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacodynamics; Therapeutic Use
- 30 Aug 2021 New trial record
- 19 Aug 2021 Results published in the Journal of Thoracic Oncology